VT
VT6.F Voyager Therapeutics Inc
- Market cap
- EUR 91.0M
- P/E
- -
- P/B
- 0.81x
- ROE
- -76.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is VT6.F undervalued?
Graham numberThe Graham number of Voyager Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Voyager Therapeutics Inc fundamental analysis
No fundamental analysis for Voyager Therapeutics Inc yet.
Voyager Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to targ…
Full company profileVoyager Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Voyager Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 14.2M | 10.1M | 7.62M | 104M | 171M | 37.4M | 40.9M | 250M | 80.0M | 40.4M | 13.0M |
| Operating Income | -41.3M | -71.9M | -91.1M | -51.7M | 27.4M | -73.6M | -50.8M | 122M | -83.3M | -132M | -111M |
| EBITDA | - | -70.3M | -89.0M | -48.9M | 31.2M | -68.5M | -44.6M | 126M | -78.6M | -128M | -107M |
| Net Income | -40.2M | -70.7M | -88.3M | -43.6M | 36.7M | -71.2M | -46.4M | 132M | -65.0M | -120M | -103M |
| EPS | - | -2.24 | -2.73 | -1.18 | 0.98 | -1.88 | -1.20 | 3.00 | -1.19 | -2.03 | -1.65 |
| Balance Sheet | |||||||||||
| Total Assets | 190M | 184M | 177M | 355M | 262M | 194M | 159M | 351M | 393M | 252M | 177M |
| Total Liabilities | 53.6M | 50.4M | 131M | 255M | 107M | 98.8M | 100M | 115M | 93.3M | 56.2M | 41.9M |
| Shareholders' Equity | 136M | 134M | 46.4M | 99.5M | 154M | 95.1M | 59.0M | 236M | 300M | 196M | 135M |
| Cash & Short-term Investments | 36.6M | 31.5M | 46.9M | 86.0M | 104M | 117M | 99.0M | 68.8M | 71.4M | 65.3M | 48.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -42.5M | -61.4M | -15.9M | 48.7M | -96.7M | -53.5M | -12.5M | 77.9M | -15.3M | -132M | -105M |
| Capital Expenditure | 5.03M | 3.99M | 4.31M | 7.72M | 12.1M | 1.61M | 2.49M | 3.26M | 3.52M | 2.60M | 18.7K |
| Free Cash Flow | - | -65.3M | -20.2M | 40.9M | -109M | -55.1M | -15.0M | 74.7M | -18.8M | -135M | -105M |
| Ratios | |||||||||||
| ROE | -29.6% | -52.7% | -190.1% | -43.8% | 23.8% | -74.9% | -78.6% | 56.0% | -21.7% | -61.1% | -76.1% |
| ROA | -21.2% | -38.3% | -49.9% | -12.3% | 14.0% | -36.7% | -29.1% | 37.7% | -16.5% | -47.5% | -58.1% |
| Net Profit Margin | -282.7% | -697.6% | -1,158.8% | -41.8% | 21.5% | -190.3% | -113.4% | 52.9% | -81.3% | -296.5% | -789.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Voyager Therapeutics Inc dividends
Voyager Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns Voyager Therapeutics Inc
- Insiders 14.81%
- Institutions 56.58%
- Public & others 28.62%
- Shares outstanding 62.2M
- Free float 44.9M
Voyager Therapeutics Inc company profile
- Company name
- Voyager Therapeutics Inc
- Ticker
- VT6.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 141
- Fiscal year end
- December
- Address
- 75 Hayden Avenue, Lexington, MA, United States, 02421
- Phone
- 857 259 5340
- Website
- voyagertherapeutics.com
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Voyager Therapeutics Inc management
6- Dr. Alfred W. Sandrock Jr., M.D., Ph.D.CEO & Director · born 1958
- Ms. Robin SwartzPresident · born 1970
- Dr. Krystof Bankiewicz M.D., Ph.D.Founder
- Dr. Mark A. Kay M.D., Ph.D.Founder · born 1958
- Ms. Amy QuinlanPrincipal Accounting Officer · born 1975
- Mr. Todd Carter Ph.D.Chief Scientific Officer · born 1970